IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Howard Hoffman who wrote (1087)	7/7/1997 10:00:00 PM
From: margie	of 1762

Article - "Moment of Decision" in new Worth Special Issue on Investing in Technology. About trials and tribulations of IDEC Pharmaceuticals and their partner Genentech, hoping to gain FDA approval for Rituxan, for low-grade non-Hodgkins lymphoma. "If approved, it'll be the first monoclonal antibody to treat cancer in the U.S. and could open the door for many similar treatments." Gives history of IDEC, and different scenarios for what if it gets approval and what if it doesn't. "Most analysts expect the committee to recommend approval, but there's a chance it won't."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next